Verge Genomics forms strategic partnership with Devano
The partnership leverages Verge's CONVERGE platform, integrating genomics, ML, and disease modeling for drug discovery. Full press release available at Devano.ai.
See the latest news and media coverage for Verge. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-powered drug discovery platform
vergelabs.comLast updated
In short: Verge Genomics rebranded as Verge Labs and shifted to a partnership model following the clinical failure of its lead ALS drug candidate.
The partnership leverages Verge's CONVERGE platform, integrating genomics, ML, and disease modeling for drug discovery. Full press release available at Devano.ai.
Biomarkers measure mobility, breathing, sleep, and speech changes in VRG50635 trial's pre-treatment period using sensors and AI. Data presented at AAN meeting.
VRG201 is an oral small molecule inhibiting CD38 to prevent weight regain and treat metabolic dysfunction. It is in IND-enabling studies, entering clinic in Q3 2025.
Lilly advances two targets validated by Verge’s CONVERGE® platform, triggering milestone payments. 83% validation rate exceeds industry standards.
Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match...
Verge Genomics' sole clinical-stage drug has failed, and the California biotech will shift to a partnership model for its AI-driven discovery platform, Endpoints News has...
Verge Genomics Online Auction opens Oct. 21st @ 10am PST BioTek Cytation 5 Imaging Reader w/ BioSpa 8 Automated Incubator Cytiva Luminescent Image Analyzer Model...
— First-in-class, oral small molecule to prevent weight regain, without need for significant lifestyle modifications — Breakthrough potential to treat...
Track Verge and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Verge and other trending companies.